2023 American Association for Cancer Research (AACR) Annual Meeting
Orlando, Fl
SITC 2022 Annual Meeting
European Association for the Study of Diabetes 2022 Annual Conference
EULAR 2021 Virtual Congress - Scleroderma, myositis and related syndromes
EULAR 2021 Virtual Congress - Progress in myositis and scleroderma research - I
Presentation: Phase 3 Trial of Lenabasum, a CB2 Agonist, for the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc)
American College of Rheumatology (“ACR”) Convergence 2020
Virtual
- Abstract #1639: Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE)
- Abstract # 1379: Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series
- Abstract #1949: CB2 Receptor Distribution and Effects of Lenabasum in Dermatomyositis In Vitro
North American Cystic Fibrosis Conference 2020
6th Systemic Sclerosis World E-Congress
- Abstract 120: Provisional American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) Score Correlates with Changes in Patient-reported Outcomes (PROs)
- Poster 158: Health Assessment Questionnaire Disability Index (HAQ-DI) and Patient Global Assessment of Health (PtGA) Correlate with Changes in Patient Reported Outcomes (PROs)
- Poster 159: Patient and Physician Opinion of Clinical Benefit at 3 Months in a Clinical Trial Correlate with Patient Reported Outcomes (PROs)
- Symposium Presentation: The Role of the Endocannabinoid System in Chronic Inflammation and Fibrosis
43rd European Cystic Fibrosis Conference
European League Against Rheumatism (EULAR) 2020 E-Congress
2019 ACR Annual Meeting
Atlanta, Georgia
Oral Presentations:
- Abstract #865: Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
- Abstract #2843: Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Poster:
ICRS 2019 Symposium
Bethesda, MD
EULAR 2019 Annual Meeting
Madrid, Spain
Oral Presentations:
Abstract #OP0241: Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Abstract #OP0325: Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects (dcSSc)
Poster Presentations:
Abstract #FRI0334: Performance of the Scleroderma Skin Patient-reported Outcome (SSPRO) in a Phase 2 Trial with Lenabasum
Abstract #SAT0303: Design of Phase 3 Study of Lenabasum for the Treatment of Dermatomyositis
Poster Tour:
Abstract #FRI0307: Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces CD4 Cell Populations and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
American College of Rheumatology (“ACR”) 2018 Annual Meeting
Chicago, IL
Presented Posters & Presentations:
- Safety and Efficacy of Lenabasum (JBT-101) in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
- Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated in an Open-Label Extension of Trial JBT101-DM-001
- Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
2018 Annual European Congress of Rheumatology
Amsterdam
Presented Posters & Presentations:
- Safety And Efficacy Of Lenabasum (JBT-101) In Diffuse Cutaneous Systemic Sclerosis Subjects Treated For One Year In An Open-Label Extension Of Trial JBT101-SSc-001
- Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated in an Open Label Extension of Trial JBT101-DM-001
- A Phase 2 Study of Safety and Efficacy of Lenabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis
American College of Rheumatology 2017 Annual Meeting
San Diego, CA
Presented Posters & Presentations:
- Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
- Prospective Validation of the Scleroderma Skin Patient-reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in An Open-Label Extension of Trial JBT101-SSc-001
- Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist
- Anabasum (JBT-101) Enhances Resolution of Inflammation in Humans
2017 North American Cystic Fibrosis Conference
Indianapolis, IN
Presented Posters:
- A Double-Blind, Placebo Controlled Phase 2 Study in Adults with Cystic Fibrosis of Anabasum, A Selective Cannabinoid Receptor Type 2 Agonist
- Anabasum Reduces Excessive Inflammatory Responses in Cystic Fibrosis Patient-Derived Lung Macrophages
- Anabasum Enhances Resolution of Bacterial-Induced Inflammation in Healthy Humans
2015 ACR Annual Meeting
San Francisco, CA
29th Annual North American Cystic Fibrosis Conference
Phoenix, AZ
Presented Posters:
38th European Cystic Fibrosis Society Conference
Brussels, Belgium
Cystic Fibrosis Workshop
The Langham Hotel, Boston, MA